SQA
MCRB icon

Simon Quick Advisors’s Seres Therapeutics MCRB Stock Holding History

Simon Quick Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1
Closed – – 425
2018
Q4 		$0 Buy
+1
New +$140 ﹤0.01% 350
2017
Q4 		– Sell
-2
Closed -$1K – 542
2017
Q3 		$1K Buy
+2
New +$547 ﹤0.01% 500
2017
Q2 		– Sell
-2
Closed – – 343
2017
Q1 		$0 Buy
+2
New +$406 ﹤0.01% 363

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Simon Quick Advisors's MCRB Position: Q1 2019 in Review

Simon Quick Advisors sold out of Seres Therapeutics (MCRB) in Q1 2019, closing a stake of 1 share.

Simon Quick Advisors first reported a position in MCRB in Q1 2017 and held it in 3 quarters. The position peaked at $1K in Q3 2017. 82 funds tracked by Wall St. Rank hold MCRB as of Q1 2019.

  • Simon Quick Advisors reported no remaining Seres Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Simon Quick Advisors sold 1 Seres Therapeutics share in Q1 2019.
  • Simon Quick Advisors first reported a position in Seres Therapeutics in Q1 2017 and held it in 3 quarters.
  • Simon Quick Advisors's Seres Therapeutics position peaked at $1K in Q3 2017.
  • 82 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2019.

Based on Simon Quick Advisors's 13F filing for Q1 2019, filed 16 Apr 2019.